Rheumazentrum Ratingen

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Rheumatoid arthritis5 trials
• Psoriatic arthritis4 trials
• Psoriasis3 trials
• Ankylosing spondylitis2 trials

Phase

• Phase 34 trials
• Phase 43 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Completed8 trials
• Active, not recruiting3 trials

Lead sponsor

• UCB Biopharma SRL2 trials
• AbbVie1 trial
• Acelyrin Inc.1 trial
• Alfasigma S.p.A.1 trial
• Bristol-Myers Squibb1 trial
• and 5 more

Running trials

• Active, not recruiting

  A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

  NCT05622708· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

  NCT05049798· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

  NCT04871919· Alfasigma S.p.A.· Source

Closed trials

• Completed

  A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

  NCT06073093· Phase 2· Sanofi· Source

• Completed

  Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· Phase 3· AbbVie· Source

• Completed

  A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is

  2022-501362-22-00· Phase 2/3· Acelyrin Inc.· Source

• Active, not recruiting

  A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

  NCT04908189· Phase 3· Bristol-Myers Squibb· Source

• Completed

  A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

  NCT04436640· Phase 3· UCB Biopharma SRL· Source

• Completed

  Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients

  NCT04485325· Phase 4· Dr. Frank Behrens· Source

• Completed

  A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

  NCT04009499· Phase 3· UCB Biopharma SRL· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Eli Lilly and Company· Source